A Randomized Phase II Trial of IL-2/IFN-alpha Plus Bevacizumab Versus IL-2/IFN-alpha in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2b; Interleukin-2
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 12 Jul 2017 This trial was completed in Denmark on 2017-05-31 according to European Clinical Trials Database record.
- 30 Aug 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 13 Jun 2011 New source identified: European Clinical Trials Database.